Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duration of PEG-IFN/Ribavirin for HCV Genotype 1
NCT00152581Phase 4Completed
- Sponsor
- UCLH
- Start
- Apr 2002
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C (HCV) (3 arms), sponsored by UCLH. Primary endpoint: Sustained Virological Response. Started Apr 2002; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00152581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152581.